Efficacy of EMCO Therapy on Serum β-hCG Levels in Case of Gestational Trophoblastic Neoplasm (GTN) at Dr. M. Djamil Hospital Padang 2019-2021

Authors

  • Attahhal Fikrian Syadiq Siregar Universitas Andalas
  • Syamel Muhammad Department of Obstetrics and Gynecology, Faculty of Medicine, Andalas University, Padang, West Sumatera, Indonesia
  • Elly Usman Department of Pharmacology, Faculty of Medicine, Andalas University, Padang, West Sumatera, Indonesia

DOI:

https://doi.org/10.25077/aoj.8.2.754-762.2024

Keywords:

Gestational Trophoblastic Neoplasm (GTN), EMCO Chemotherapy, Serum B-hCG Levels

Abstract

Backgrounds: Etoposide, Methotrexate, Cyclophosphamide, and Vincristine (EMCO) Chemotherapy is used as an alternative therapy for patients with a diagnosis of Gestational Trophoblastic Neoplasm (GTN) at Dr. M. Djamil Hospital Padang because Actinomycin D has not been included in the National Formulation (FORNAS).

Purpose: To determine the efficacy of EMCO therapy with limited Actinomycin D on serum β-hCG levels in Gestational Trophoblastic Neoplasm (GTN) cases at Dr. M. Djamil Padang Hospital in 2019-2021.

Methods: The type of research used is numerical comparative analytics with a cross sectional approach. The number of samples was 17 GTN patients who had done EMCO chemotherapy and checked β-hCG levels before and after chemotherapy. The research was conducted from April to October 2022 at Dr. M. Djamil Hospital Padang. Data processing using total sampling technique and tested using Wilcoxon Test.

Results: Most GTN patients were found to be <40 years old (64,7%), history of molar hydatidiform pregnancy (47,1%), last pregnancy interval <4 months (58,8%), β-hCG level before chemotherapy ranged from 104-105 mIU/mL (52,9%), tumor size >5 cm (58,8%), metastasis location in the internal genital tract (35,5%), and patients who did not have metastasis (52,9%).

Conclusion: There was a significant decrease in β-hCG levels after chemotherapy using EMCO for three cycles in patients with a diagnosis of GTN.

Downloads

Published

2024-07-25

Issue

Vol. 8 No. 2 (2024)

Section

RESEARCH ARTICLE

License

Copyright (c) 2024 Attahhal Fikrian Syadiq Siregar

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

Authors who publish with this journal agree to the following terms:

  1. Authors retain the copyright of published articles and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

License:

Andalas Obstetrics and Gynecology Journal (AOJ) is published under the terms of the Creative Commons Attribution 4.0 International License. This license permits anyone to copy and redistribute this material in any form or format, compose, modify, and make derivatives of this material for any purpose, including commercial purposes, as long as they credit the author for the original work.